198 related articles for article (PubMed ID: 37597153)
21. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
Rodriguez-Otero P; Ayers D; Cope S; Davies FE; Delforge M; Mojebi A; Jansen JP; Weisel K; Hege K; Dhanasiri S
Leuk Lymphoma; 2021 Oct; 62(10):2482-2491. PubMed ID: 33896344
[TBL] [Abstract][Full Text] [Related]
22. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.
Lee DH; Kumar A; Mohammed T; Peres LC; Alsina M; Bachmeier C; Blue BJ; Brayer J; Chandrasekhar S; Grajales Cruz A; De Avila G; Elmariah H; Faramand R; Freeman C; Jain M; Khadka S; Khimani F; Liu H; Nishihori T; Oswald LB; Castaneda Puglianini OA; Shain KH; Smith E; Baz RC; Locke FL; Oliveira GH; Alomar M; Hansen DK
Blood Adv; 2023 Aug; 7(16):4247-4257. PubMed ID: 37307173
[TBL] [Abstract][Full Text] [Related]
23. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.
Zanwar S; Sidana S; Shune L; Puglianini OC; Pasvolsky O; Gonzalez R; Dima D; Afrough A; Kaur G; Davis JA; Herr M; Hashmi H; Forsberg P; Sborov D; Anderson LD; McGuirk JP; Wagner C; Lieberman-Cribbin A; Rossi A; Freeman CL; Locke FL; Richard S; Khouri J; Lin Y; Patel KK; Kumar SK; Hansen DK
J Hematol Oncol; 2024 Jun; 17(1):42. PubMed ID: 38845015
[TBL] [Abstract][Full Text] [Related]
24. Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Connarn JN; Witjes H; van Zutphen-van Geffen M; de Greef R; Campbell TB; Hege K; Zhou S; Lamba M
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1687-1697. PubMed ID: 36794354
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Yamamoto C; Minakata D; Yokoyama D; Furuki S; Noguchi A; Koyama S; Oyama T; Murahashi R; Nakashima H; Ikeda T; Kawaguchi SI; Hyodo K; Toda Y; Ito S; Nagayama T; Umino K; Morita K; Ashizawa M; Ueda M; Hatano K; Sato K; Ohmine K; Fujiwara SI; Kanda Y
Transplant Cell Ther; 2024 Jan; 30(1):118.e1-118.e15. PubMed ID: 37802181
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.
Hashmi H; Hansen DK; Peres LC; Puglianini OC; Freeman C; De Avila G; Sidana S; Shune L; Sborov DW; Davis J; Wagner C; Kocoglu MH; Atrash S; Voorhees P; Simmons G; Ferreri C; Kalariya N; Anderson LD; Afrough A; Dima D; Khouri J; McGuirk J; Locke F; Baz R; Patel KK; Alsina M
Haematologica; 2024 May; 109(5):1514-1524. PubMed ID: 37855036
[TBL] [Abstract][Full Text] [Related]
27. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.
Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T
Front Immunol; 2022; 13():991092. PubMed ID: 36119032
[TBL] [Abstract][Full Text] [Related]
28. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
[TBL] [Abstract][Full Text] [Related]
29. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: a review of recent advances.
Tu W; Xiao Y; Wang Y; Luo R; Chen ZS
Drugs Today (Barc); 2022 Mar; 58(3):117-132. PubMed ID: 35274631
[TBL] [Abstract][Full Text] [Related]
30. The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
Ghanem B; Shi L
BioDrugs; 2022 Nov; 36(6):773-780. PubMed ID: 36167952
[TBL] [Abstract][Full Text] [Related]
31. Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma.
Ayers D; Cope S; Towle K; Mojebi A; Marshall T; Dhanda D
BMC Med Res Methodol; 2022 Oct; 22(1):272. PubMed ID: 36243687
[TBL] [Abstract][Full Text] [Related]
32. BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.
Fang J; Zhou F
Ann Hematol; 2024 Apr; 103(4):1069-1083. PubMed ID: 37704875
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience of CAR T cells for multiple myeloma.
Simmons GL; Satta T; Castaneda Puglianini O
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101306. PubMed ID: 34625232
[TBL] [Abstract][Full Text] [Related]
34. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
[TBL] [Abstract][Full Text] [Related]
35. Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma.
Kirchberg J; Fischer L; Born P; Brunner F; Morgner C; Fürst D; Heyn S; Bach E; Brueckner M; Jentzsch M; Wang SY; Böttcher S; Franke GN; Schrezenmeier H; Platzbecker U; Merz M; Vučinić V
Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38821728
[TBL] [Abstract][Full Text] [Related]
36. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.
Logue JM; Peres LC; Hashmi H; Colin-Leitzinger CM; Shrewsbury AM; Hosoya H; Gonzalez RM; Copponex C; Kottra KH; Hovanky V; Sahaf B; Patil S; Lazaryan A; Jain MD; Baluch A; Klinkova OV; Bejanyan N; Faramand RG; Elmariah H; Khimani F; Davila ML; Mishra A; Blue BJ; Grajales-Cruz AF; Castaneda Puglianini OA; Liu HD; Nishihori T; Freeman CL; Brayer JB; Shain KH; Baz RC; Locke FL; Alsina M; Sidana S; Hansen DK
Blood Adv; 2022 Dec; 6(24):6109-6119. PubMed ID: 35939783
[TBL] [Abstract][Full Text] [Related]
37. [Clinical development of chimeric antigen receptor T-cell therapy in multiple myeloma].
Goto H
Rinsho Ketsueki; 2022; 63(6):580-588. PubMed ID: 35831191
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma.
Kapinos KA; Hu E; Trivedi J; Geethakumari PR; Kansagra A
Cancer Control; 2023; 30():10732748221142945. PubMed ID: 36651055
[TBL] [Abstract][Full Text] [Related]
39. Sequence not salvage.
Sborov DW; Fortuna GG; Hayden PJ
Br J Haematol; 2024 May; 204(5):1590-1592. PubMed ID: 38563345
[TBL] [Abstract][Full Text] [Related]
40. French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.
Ferment B; Lambert J; Caillot D; Lafon I; Karlin L; Lazareth A; Touzeau C; Leleu X; Moya N; Harel S; Perrot A; Bories P; Vincent L; Lamure S; Mohty M; Malard F; Manier S; Yakoub-Agha I; Schiano De Colella JM; Brisou G; Talbot A; Decaux O; Houot R; Le Gouill S; Bigot N; Facon T; Corre J; Moreau P; Arnulf B;
Br J Haematol; 2024 May; ():. PubMed ID: 38747092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
